Anede Nada, Ouassaf Mebarka, Rengasamy Kannan R R, Khan Shafi Ullah, Alhatlani Bader Y
Group of Computational and Medicinal Chemistry, LMCE Laboratory, University of Biskra, Biskra, Algeria.
Laboratory of Natural Products and Medicinal Chemistry (LNPMC), Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai, 602105, India.
Mol Biotechnol. 2024 Dec 28. doi: 10.1007/s12033-024-01357-6.
The Zika virus (ZIKV), an arbovirus within the Flavivirus genus, is associated with severe neurological complications, including Guillain-Barré syndrome in affected individuals and microcephaly in infants born to infected mothers. With no approved vaccines or antiviral treatments available, there is an urgent need for effective therapeutic options. This study aimed to identify new natural compounds with inhibitory potential against the NS2B-NS3 protease (PDB ID: 5LC0), an essential enzyme in viral replication. An e-pharmacophore model was generated using a five-point (ADDRR) feature approach in the PHASE module of Schrodinger and used for the virtual screening of 26,689 natural compounds from the PubChem database. The screening yielded 14,277 prioritized compounds based on fitness scores, further refined through extra precision (XP) docking in GLIDE, resulting in 24 compounds. Eight top hits were selected following ADME analysis with SwissADME, and toxicity screening with ProTox-II identified four non-toxic lead candidates. Molecular dynamic simulations confirmed the stability of the three most promising leads, CID 44418637, CID 163078083, and CID 68734190, with binding affinities of - 7.721, - 8.226, and - 8.307 kcal/mol, respectively. MM/GBSA analysis revealed that Compounds 68734190 (- 50.192 kcal/mol) and 163078083 (- 49.947 kcal/mol) possess superior binding affinities to the ZIKV NS2B-NS3 protease compared to the reference compound (- 38.347 kcal/mol). Given their natural origin, these compounds may offer safer options to mitigate severe ZIKV-related symptoms while providing a favourable safety and pharmacokinetic profile. This study lays the groundwork for developing targeted ZIKV therapies, potentially addressing a significant unmet need in public health by reducing the incidence of ZIKV-related complications. Further experimental validation is required to confirm efficacy and address potential development challenges.
寨卡病毒(ZIKV)是黄病毒属的一种虫媒病毒,与严重的神经并发症有关,包括受感染个体的吉兰 - 巴雷综合征以及感染母亲所生婴儿的小头畸形。由于目前尚无获批的疫苗或抗病毒治疗方法,因此迫切需要有效的治疗选择。本研究旨在鉴定对NS2B - NS3蛋白酶(PDB ID:5LC0)具有抑制潜力的新型天然化合物,该蛋白酶是病毒复制中的一种关键酶。使用薛定谔软件PHASE模块中的五点(ADDRR)特征方法生成了一个电子药效团模型,并用于从PubChem数据库中对26,689种天然化合物进行虚拟筛选。基于适合度分数,筛选出了14,277种优先化合物,通过GLIDE中的高精度(XP)对接进一步优化,得到了24种化合物。使用SwissADME进行ADME分析,并使用ProTox-II进行毒性筛选后,选择了8个最佳命中化合物,确定了4种无毒的先导候选物。分子动力学模拟证实了三种最有前景的先导化合物CID 44418637、CID 163078083和CID 68734190的稳定性,其结合亲和力分别为 - 7.721、- 8.226和 - 8.307千卡/摩尔。MM/GBSA分析表明,与参考化合物(- 38.347千卡/摩尔)相比,化合物68734190(- 50.192千卡/摩尔)和163078083(- 49.947千卡/摩尔)对寨卡病毒NS2B - NS3蛋白酶具有更高的结合亲和力。鉴于这些化合物的天然来源,它们可能提供更安全的选择来减轻与寨卡病毒相关的严重症状,同时提供良好的安全性和药代动力学特征。本研究为开发针对性的寨卡病毒疗法奠定了基础,有望通过降低寨卡病毒相关并发症的发生率来满足公共卫生领域一项重大的未满足需求。需要进一步的实验验证来确认疗效并应对潜在的开发挑战。